Washington, D.C. – U.S. Senator Pat
Toomey (R-Pa.), the chairman of the Senate Finance Committee Subcommittee on
Health Care, will convene a hearing examining the testing and treatment for
Alzheimer’s disease and the fiscal implications of the disease on our federal
healthcare programs on Wednesday, December 16th at
2:30 PM.
Last year, the Senate Finance Committee Subcommittee on Health
Care held a hearing on the barriers to treatment and care for Alzheimer’s patients.
Chairman Toomey and Ranking Member Debbie Stabenow (D-Mich.) also sought input from stakeholders – providers,
researchers, patients, patient advocacy groups, states, and others – to
inform the development of regulatory recommendations and potential future
legislation. The senators sent a letter to the Administration in
October, requesting certain regulatory actions to improve care for Alzheimer’s
patients.
What: Hearing: “The Alzheimer’s Crisis: Examining Testing and Treatment Pipelines and Fiscal Implications.”
When: Wednesday, December 16th at
2:30 PM.
Witnesses:
Nikolay Dokholyan, Ph.D., M.S.
G. Thomas Passananti, Professor and Vice Chair for Research
Pennsylvania
State College of Medicine, Hershey, Pa.
Randall
J. Bateman, M.D.
Charles F. and Joanne Knight Distinguished Professor of Neurology,
Director, Dominantly Inherited Alzheimer's Network (DIAN), DIAN Trials Unit
Washington
University School of Medicine, St. Louis, Mo.
Richard Mohs, Ph.D.
Chief Scientific Officer
Global
Alzheimer’s Platform Foundation, Chicago, Ill.
Maria Carrillo, Ph.D.
Chief
Science Officer
Alzheimer’s
Association, Chicago, Ill.